Fulgent Genetics (MEX:FLGT) 6-1 Month Momentum % : -14.19% (As of Jun. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-22), Fulgent Genetics's 6-1 Month Momentum % is -14.19%.

The industry rank for Fulgent Genetics's 6-1 Month Momentum % or its related term are showing as below:

MEX:FLGT's 6-1 Month Momentum % is ranked worse than
80.26% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: -6.88 vs MEX:FLGT: -14.19

Competitive Comparison of Fulgent Genetics's 6-1 Month Momentum %

For the Diagnostics & Research subindustry, Fulgent Genetics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fulgent Genetics's 6-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's 6-1 Month Momentum % falls into.

Fulgent Genetics (MEX:FLGT) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics (MEX:FLGT) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Fulgent Genetics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics (MEX:FLGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.